Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis

See the original post:
Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh